Saratov JOURNAL of Medical and Scientific Research

Changes in vascular wall stiffness and central aortic pressure in women of early post-menopausal period and the possibilities of correction of the revealed disturbances

Year: 2017, volume 13 Issue: №1 Pages: 034-041
Heading: Internal Diseases Article type: Original article
Authors: Tolstov S.N., Salov I.A., Rebrov A.P.
Organization: Saratov State Medical University
Summary:

Measurement of the central aortic pressure and the augmentation may have additional benefits for characterizing the state of the cardiovascular system than the only stiffness of the vascular wall. The purpose of the study is to assess the changes of indicators of central aortic pressure and arterial stiffness in women of early postmenopausal period, against the background of the prolonged use of menopausal hormone therapy 1 mg E2 / 2mg DRSP. Material and Methods. The study included 162 women in early postmenopause. The subjects were divided into 2 groups: primary — 84 patients, which was appointed menopausal hormone therapy 1 mg E2 / 2mg of DRSP (drug "Angelique", Bayer), control group — 78 women who did not receive menopausal hormone therapy. The duration of observation is 5.2 years. ABPM was performed with the evaluation indicators of arterial stiffness (RWTT, Alx, ASI, AASI, (dP/dt) max.), central aortic pressure, aoPW. Results. Initial aoPW increase was detected in 15 (21.4%) women of the main group and in 19 (24.3%) control group patients (p=0,4). The women in both groups showed an increase to the end of the study aoPW more pronounced in women of control group. Increasing falls detected in 25 (29.7%) women of the main group and in 25 (32%) women of control group (p=0.84). It was noted that in women in both groups a significant decrease of central aortic pressure has been matched. In women of the main group to the end of the study there was a reduction in pulse pressure from 38,4±6,2 to 35,3±4,19mm Hg (p<0,001) and the absence of changes in women drops the control group. It is noted a significant increase of Alxao in patients of control group and no change in women of the main group. ASI revealed a decrease in women of the main group with 132.0 (121.0; 142.0) to 127.0 (115.5; 137.0) to the end of the study, and an increase from 133.0 (111.0; 155.0) to 148.0 (134.2; 171.0) in women in the control group (p<0.01). Decrease of AASI in women of the main group to 0.379 (0.320; 0.463) to 0.264 (0.203; 0.329), (p<0.001)and no change in the control group of women has been detected. Conclusion. The measurement of the central aortic pressure and the augmentation may have additional benefits for characterizing the state of the cardiovascular system. The positive changes in arterial stiffness and reflected waves, determining the value of central aortic pressure, on the background of long-term menopausal hormone therapy combined 1 mg E2 / 2 mg DRSP.

Bibliography:
1. Oganov RG, Maslennikova GYa. Demographic trends in the Russian Federation: the impact of cardiovascular disease. Cardiovascular Therapy and Prevention 2012; 11 (1): 5-10
2. Lukjyanov MM, Boytsov SA. Arterial wall rigidity as cardiovascular risk and prognostic factor in clinical practice. Russian Heard Journal 2010; 3 (9): 156-59
3. Pini R, Cavallini МС, Palmieri V, et al. Central but not brachial blood pressure predicts cardiovascular events in an unselected geriatric population. J Am Coll Cardiol 2008; 51: 2432-9
4. Yureneva SV, llyina LM, Smetnik VP Aging female reproductive system: from theory to clinical practice. Part I: Clinical and Endocrine characteristics of the stages of reproductive aging women. Obstetrics and gynecology 2014; 3: 21-27
5. Villiers TJ de, Pines A, Panay N, et al. On behalf of the International Menopause Society. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 2013; 16:316-37
6. Menopausal hormone therapy and health preservation of women in adulthood: Clinical recommendations (treatment protocols): Letter of the Ministry of Health of Russia from 02.10.2015 № 15-4/10/2-5804
7. Laurent S, Cockcroft J, Bortel LV, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27 (21): 2588-2605
8. Gambacciani M, Pepe A. Vasomotor symptoms and cardiovascular risk. Climacteric 2009; (Suppl 1): 32-5
9. Guidelines for the management of arterial hypertension / The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and of the European Society of Cardiology; ESH/ESC 2013. Russ J Cardiol 2014; 1 (105): 7-94
10. Woodard GA. Mehta VG., Mackey RH, et al. C-reactive protein is associated with aortic sriffness in a cohort of African American and white women transitioning through menopause. Menopause 2011; 18(12): 1291-97
11. Williams B, Lacy PS, Thorn SM, et al. CAFE Investigators. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) Study. Circulation 2006; 113: 1213-25
12. Kaibe M, Ohishi M, Komai N, et al. Arterial stiffness index: A new evaluation for arterial stiffness in elderly patients with essential hypertension. Geriatrics and Gerontology International 2002; 2: 199-205
13. Dolan E, Thijs L, Li Y, et al. Ambulatory Arterial Stiffness Index as a Predictor of Cardiovascular Mortality in the Dublin Outcome Study. Hypertension 2006; 47: 365-70
14. Shufelt C, Elboudwarej O, Johnson BD, et al. Carotid artery distensibility and hormone therapy and menopause: the Los Angeles Atherosclerosis Study. Menopause 2016; 23 (2): 150-57
15. Baranova El, Bolshakova 00, Zazerskiya IE, Yusipova TX. The effect of hormone replacement therapy with drospirenone on the structural and functional parameters of cardiovascular system in women with hypertension and abdominal obesity in postmenopausal women. Hypertension 2015; 21 (4): 327-77
16. Simoncini Т, Fu XD, Caruso A, et al. Drospirenone increases endothelial nitric oxide synthesis via a combined action on progesterone and mineralocorticoid receptors. Hum Reprod 2007; 22 (8): 2325-34
17. Salov IA, Tolstov SN, Mychka VB, et al. Menopausal metabolic syndrome and hormonal replacement therapy. Obstetrics and gynecology 2011; 2: 24-31.

AttachmentSize
2017_01_034-041.pdf287.4 KB

No votes yet